Presentation: Fructooligosaccharides Intake during Pregnancy and Lactation Increases Gut <I>Bifidobacterium</I> and IL-27 in Breast Milk ( World Allergy Congress)

Friday, 16 October 2015: 16:45 - 17:00

Room R2 ABC (Floor 3) (Coex Convention Center)

Yuji Fujita, MD , Chiba University, Chiba, Japan

Yoshitaka Nakamura, PhD , Division of Research and Development, Meiji Co Limited, Kanagawa, Japan

Yuzaburo Inoue, MD, PhD , Chiba University, Chiba, Japan

Naoki Shimojo, MD, PhD , Chiba University, Chiba, Japan

Yoichi Kohno, MD, PhD , Chiba University, Chiba, Japan

Shuichi Suzuki, MD, PhD , National Shimoshizu Hospital, Chiba, Japan

Naoko Ozawa, PhD , Chiba University, Chiba, Japan

Takayuki Kubota , Chiba University, Chiba, Japan

Shuji Ikegami, PhD , Division of Research and Development, Meiji Co Limited, Kanagawa, Japan

Ken Nonaka, PhD , Department of Human Genome Research, Kazusa DNA Research Institute, Chiba, Japan

Osamu Ohara, PhD , Department of Human Genome Research, Kazusa DNA Research Institute, Chiba, Japan

Kentaro Masuda, MD , Masuda Maternity Clinic, Chiba, Japan

Background: We previously reported that the consumption of fructooligosaccharides (FOS) by pregnant and lactating women increases the production of IL-27 in breast milk in a randomized, placebo-controlled, double-blind trial (Kubota, et al. 2013), but the underlying mechanism remains to be clarified.

Methods: Healthy pregnant woman were enrolled with written informed consent. Subjects (84 individuals) were randomly assigned to the FOS (Meioligo-P, obtained from Meiji Food Materia Company Limited) (FOS, n 41) or sucrose (placebo, n43) intake groups. Trial compound (4 g) was taken after breakfast and supper daily from 26 weeks of gestation to 1 month after delivery. Colostrum samples were collected during hospitalization after childbirth and concentration of IL-27 was measured by ELISA. Fecal samples at 26 and 36 weeks of gestation were collected at home or the hospital by the subjects and the gut microbiota were quantified by quantitative real-time PCR.

Results: After excluding subjects with insufficient test compound intake, 29 in placebo and 34 in FOS groups were analyzed. There were no differences of the characteristics between 2 groups. The concentrations of IL-27 in colostrum samples were significantly higher in the FOS group (range: <0.156–46.6 ng/ml; median: 2.4 ng/ml) than in the placebo group (range: <0.156–95.8 ng/ml; median: 0.2 ng/ml) (P<0.05). Fecal numbers of Bifidobacterium were significantly increased in the FOS group but not the in the placebo group and were significantly higher in the FOS group (range: 8.9–11.0 log₁₀ cfu/g; median: 10.4 log₁₀ cfu/g) than in the placebo group (range: 8.8–10.72 log₁₀ cfu/g; median: 10.1 log₁₀ cfu/g) after the intervention (P<0.05). The concentrations of IL-27 in colostrum showed weak correlation to the Bifidobacteriumnumbers of 36 weeks of gestation.

Conclusions: Our data suggest that mother's intake of prebiotics increases IL-27 expression in breast milk by modulating gut microbiota.

9-6OAS Fructooligosaccharides Intake during Pregnancy and Lactation Increases Gut Bifidobacterium and IL-27 in Breast Milk